Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor and Melphalan (FALG with L-PAM) as a Reduced Toxicity Conditioning Regimen in Children with Acute Leukemia

被引:13
作者
Kato, Koji [1 ]
Yoshida, Nao [1 ]
Matsumoto, Kimikazu [1 ]
Matsuyama, Takaharu [1 ]
机构
[1] Japanese Red Cross Nagoya First Hosp, Childrens Med Ctr, Dept Pediat Hematol & Oncol, Nagoya, Aichi 4538511, Japan
关键词
bone marrow transplantation (BMT); late effects; leukemia; BONE-MARROW-TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; HIGH-DOSE CYTARABINE; VERSUS-HOST-DISEASE; HEMATOLOGIC MALIGNANCIES; LATE COMPLICATIONS; ALLOGENEIC TRANSPLANTATION; PREPARATIVE REGIMENS; CELL TRANSPLANTATION; CHILDHOOD-CANCER;
D O I
10.1002/pbc.24922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe conventional conditioning regimen for patients with leukemia prior to allogeneic stem cell transplantation is myeloablation to eradicate residual leukemic cells and host immunocompetent cells. This helps prevent leukemic relapse as well as rejection after transplantation. A myeloablative conditioning regimen with busulfan (BU) or total body irradiation (TBI) is effective for eradication of leukemic cells but is also associated with significant toxicities in the acute or late phase in pediatric patients. In an effort to minimize these adverse effects, we conducted bone marrow transplantation (BMT) from unrelated volunteer donors using a conditioning regimen without BU or TBI. ProcedureTen patients with acute leukemia in first or second remission were given a non-BU, non-TBI conditioning regimen, which consisted of fludarabine (FLU), cytarabine (CA), and melphalan (L-PAM) after FLAG combined with L-PAM. ResultsEngraftment was obtained in all patients, and two patients died of relapse. Eight of 10 patients have been disease-free for a median of 126 months (116-142) after transplantation. The overall survival, event-free survival, relapse rate, and treatment-related mortality were 80.0%, 80.0%, 20.0% and 0.0%, respectively. In female patients, spontaneous menstruation with normal luteinizing hormone (LH), follicle stimulating hormone (FSH), and estradiol (E2) levels was observed in all four patients at post-pubertal age. ConclusionsThis conditioning regimen of FLAG combined with L-PAM (which did not contain BU and TBI) was associated with good outcomes and minimal late adverse effects in children with acute leukemia who have undergone allogeneic BMT from unrelated volunteer donors. Pediatr Blood Cancer 2014;61:712-716. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:712 / 716
页数:5
相关论文
共 37 条
  • [1] Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia
    Aricò, M
    Valsecchi, MG
    Camitta, B
    Schrappe, M
    Chessells, J
    Baruchel, A
    Gaynon, P
    Silverman, L
    Janka-Schaub, G
    Kamps, W
    Pui, CH
    Masera, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) : 998 - 1006
  • [2] ATKINSON K, 1990, BLOOD, V75, P2459
  • [3] Defining the Intensity of Conditioning Regimens: Working Definitions
    Bacigalupo, Andrea
    Ballen, Karen
    Rizzo, Doug
    Giralt, Sergio
    Lazarus, Hillard
    Ho, Vincent
    Apperley, Jane
    Slavin, Shimon
    Pasquini, Marcelo
    Sandmaier, Brenda M.
    Barrett, John
    Blaise, Didier
    Lowski, Robert
    Horowitz, Mary
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) : 1628 - 1633
  • [4] Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study
    Balduzzi, A
    Valsecchi, MG
    Uderzo, C
    De Lorenzo, P
    Klingebiel, T
    Peters, C
    Stary, J
    Felice, MS
    Magyarosy, E
    Conter, V
    Reiter, A
    Messina, C
    Gadner, H
    Schroppe, M
    [J]. LANCET, 2005, 366 (9486) : 635 - 642
  • [5] Cesaro S, 2005, HAEMATOLOGICA, V90, P1396
  • [6] Champlin R, 2003, ONCOLOGY-NY, V17, P94
  • [7] Endocrinological late complications after hematopoietic SCT in children
    Cohen, A.
    Bekassy, A. N.
    Gaiero, A.
    Faraci, M.
    Zecca, S.
    Tichelli, A.
    Dini, G.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 (Suppl 2) : S43 - S48
  • [8] USE OF GRANULOCYTE-COLONY-STIMULATING FACTOR BEFORE, DURING, AND AFTER FLUDARABINE PLUS CYTARABINE INDUCTION THERAPY OF NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROMES - COMPARISON WITH FLUDARABINE PLUS CYTARABINE WITHOUT GRANULOCYTE-COLONY-STIMULATING FACTOR
    ESTEY, E
    THALL, P
    ANDREEFF, M
    BERAN, M
    KANTARJIAN, H
    OBRIEN, S
    ESCUDIER, S
    ROBERTSON, LE
    KOLLER, C
    KORNBLAU, S
    PIERCE, S
    FREIREICH, E
    DEISSEROTH, A
    KEATING, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 671 - 678
  • [9] Non-endocrine late complications in children after allogeneic haematopoietic SCT
    Faraci, M.
    Bekassy, A. N.
    De Fazio, V.
    Tichelli, A.
    Dini, G.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 (Suppl 2) : S49 - S57
  • [10] GANDHI V, 1989, BLOOD, V74, P2070